Precision BioSciences, Inc. cash flow to debt ratio of -228.56% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Precision BioSciences, Inc.'s free cash flow has decreased 12.32% from $-58.70M last year to $-65.93M, signaling decreasing performance

Precision BioSciences, Inc.'s debt to equity ratio is 0.37, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Precision BioSciences, Inc.'s debt has decreased relative to shareholder equity from 0.53 last year to 0.37 today, signaling strengthened financials

Precision BioSciences, Inc. has negative EBITDA, making leverage ratio unreliable

Precision BioSciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Precision BioSciences, Inc.'s profit margin has decreased (-1.05K%) in the last year from 10.43% to -98.70%, signaling decreasing performance

Precision BioSciences, Inc.'s short-term assets of $118.74M exceed its short-term liabilities of $8.91M

Precision BioSciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Precision BioSciences, Inc.'s return on equity of -81.24%, is lower than 15.00%, indicating bad performance

Precision BioSciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Precision BioSciences, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Precision BioSciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Precision BioSciences, Inc. has negative free cash flow, indicating cash burn

Precision BioSciences, Inc.'s yearly earnings has decreased -750.33% since last year from $7.17M to $-46.61M, signaling decreasing performance

Precision BioSciences, Inc.'s yearly revenue has decreased -50.12% since last year from $68.70M to $34.26M, signaling decreasing performance

ROIC -28.40% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Precision BioSciences, Inc.'s 3-year revenue CAGR of 10.93% is positive, indicating growing revenue over the past 3 years

Precision BioSciences, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Precision BioSciences, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Precision BioSciences, Inc. has insufficient data to evaluate this check.

Precision BioSciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Precision BioSciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Precision BioSciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Precision BioSciences, Inc. has insufficient data to evaluate this check.

Precision BioSciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Precision BioSciences, Inc. has a price-to-book ratio of 1.23x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Precision BioSciences, Inc. has a price-to-sales ratio of 2.07x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue